The THRIVE score strongly predicts outcomes in patients treated with the Solitaire device in the SWIFT and STAR trials.

ABSTRACT:

Background

The Totaled Health Risks in Vascular Events (THRIVE) score strongly predicts clinical outcome, mortality, and risk of thrombolytic haemorrhage in ischemic stroke patients, and performs similarly well in patients receiving intravenous tissue plasminogen activator, endovascular stroke treatment, or no acute treatment. It is not known if the THRIVE score predicts outcomes with the Solitaire endovascular stroke treatment device.

Aims

To validate the relationship between the THRIVE score and outcomes after treatment with the Solitaire endovascular stroke treatment device.

Methods

The study conducted a retrospective analysis of the prospective SWIFT and STAR trials to examine the relationship between THRIVE and outcomes after treatment with the Solitaire device.

SUBMITTER: Flint AC 

PROVIDER: S-EPMC4160885 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature